The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort.

Autor:	Cardoso AC; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Cravo C; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Calçado FL; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Rezende G; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Campos CFF; Anatomopathology Department, Rede D'Or São Luiz., Neto JMA; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Luz RP; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Soares JAS; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Moraes-Coelho HS; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Leite NC; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro., Perez RM; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro.; Gastroenterology Department, University of the State of Rio de Janeiro.; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil., Villela-Nogueira CA; Hepatology Unit, Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro.
Jazyk:	angličtina
Zdroj:	European journal of gastroenterology & hepatology [Eur J Gastroenterol Hepatol] 2020 Feb; Vol. 32 (2), pp. 231-238.
DOI:	10.1097/MEG.0000000000001496
Abstrakt:	Objectives: Recently, controlled attenuation parameter (CAP) was incorporated for XL probe. However, its performance through M and XL probes has been scarcely evaluated in nonalcoholic fatty liver disease (NAFLD). The performance of probes regarding transient elastography by Fibroscan is still under debate. Aim: Compare the performance of CAP and transient elastography in NAFLD patients obtained through XL with M probes using histological analysis as gold standard. Methods: NAFLD patients underwent liver biopsy and FibroScan/CAP with M and XL probes the same day. C-statistic evaluated CAP performance in the identification of moderate/severe (≥33%) and severe (≥66%) steatosis by both probes and transient elastography performance for identification of significant fibrosis (≥F2). Results: Eighty-one patients (74% female; age 54.2 ± 9.9 years; BMI 32.8 ± 5.2/ BMI ≥ 25 92.6%; 96% metabolic syndrome; 60% diabetes mellitus) were included. Mean CAP with M and XL probes was 314 ± 39 and 325 ± 47 dB/m, respectively. The areas under receiver operating characteristic curves (AUROCs) of the M and XL probes for steatosis detection ≥33% were 0.75 (0.64-0.84) and 0.76 (0.65-0.84) (P = 0.95) and for steatosis ≥66% 0.83 (0.73-0.90) and 0.82 (0.71-0.89) (P = 0.73), respectively, with similar performances for both degrees of steatosis. Regarding transient elastography, AUROCs of M and XL probes for ≥F2 were 0.82 (0.71-0.93) and 0.80 (0.69-0.92) (P = 0.66). Conclusion: Performance of M and XL probes is similar for the diagnosis of moderate and severe steatosis and significant fibrosis even on a overweight population with NAFLD.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu